Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study reveals hidden fat in liver and pancreas of hepatitis b patients

NCT ID NCT07175688

Knowledge-focused Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at 217 adults with chronic hepatitis B to see how common fatty liver and fatty pancreas are in obese versus lean patients. Researchers used ultrasound and a special liver stiffness test to measure fat and scarring. The goal was to learn more about how these conditions overlap in people with hepatitis B.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors better understand how fatty liver and fatty pancreas affect people with chronic hepatitis B, potentially guiding future monitoring or treatment strategies.
What could go wrong
This is an observational study that only measures conditions at one point in time. It cannot prove cause and effect, and results may not apply to all hepatitis B patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

217 people

The number who actually took part.

Started

Apr 2022

Finished

Jan 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study was carried out in the Tropical Medicine and Infectious Diseases Department, Tanta University.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older. * Both sexes. * Chronic hepatitis B patients. Exclusion Criteria: * Hepatitis C virus (HCV) antibody positive. * Hepatocellular carcinoma (HCC). * Human immunodeficiency viruses (HIV). * Pregnancy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic hepatitis B are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hepatitis B LEAN Metabolic associated fatty liver disease OBESE Pancreatic steatosis

Contacts and locations

Locations

  • Tanta University

    Tanta, El-Gharbia, 31527, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.